Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/8/2024 | $109.00 | Buy | Redburn Atlantic |
| 9/3/2024 | Overweight | Cantor Fitzgerald | |
| 5/31/2024 | $70.00 | Overweight | Piper Sandler |
| 3/7/2024 | $81.00 | Overweight | Morgan Stanley |
| 1/4/2024 | $65.00 → $71.00 | Buy | Needham |
| 12/19/2023 | $66.00 | Sector Outperform | Scotiabank |
| 10/30/2023 | Outperform | TD Cowen | |
| 10/17/2023 | $52.00 | Buy | UBS |
-- Recently released ASH abstracts for the company's Phase 1 and iMMagine-1 studies investigating anito-cel in relapsed or refractory multiple myeloma patients continue to demonstrate durability and a manageable safety profile -- -- 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached -- -- Preliminary results from 58 patients enrolled in the Phase 2 pivotal iMMagine-1 study demonstrated 95% ORR and 62% CR/sCR at a median follow-up of 10.3 months; additional patients with a more recent data cut will be presented during an oral presentation -- -- No delayed neurotoxicities have been observ
-- 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached -- -- Preliminary results from 58 patients enrolled in the Phase 2 pivotal iMMagine-1 study demonstrated 95% ORR and 62% CR/sCR at a median follow-up of 10.3 months; additional patients with a more recent data cut will be presented during an oral presentation -- -- No delayed neurotoxicities have been observed to date with anito-cel, including no parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome across the Phase 1 and iMMagine-1 studies in the more than 140 patients dosed -- -- First patient dosed in iMMagine-3 s
-- Earned a $68M milestone payment from Kite for iMMagine-1 enrollment -- -- Submitted an abstract for the iMMagine-1 study at the 66th ASH Annual Meeting -- -- The global Phase 3 trial, iMMagine-3, has been initiated by Kite -- -- U.S. FDA clears anito-cel IND application for myasthenia gravis, an autoimmune disease -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the second quarter ended June 30, 2024. "We continue to make significant strides as we accelerate our business," said R
Redburn Atlantic initiated coverage of Arcellx with a rating of Buy and set a new price target of $109.00
Cantor Fitzgerald initiated coverage of Arcellx with a rating of Overweight
Piper Sandler initiated coverage of Arcellx with a rating of Overweight and set a new price target of $70.00
-- Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading reliable manufacturing -- -- Arcellx to receive $225M upfront payment; $100M equity investment; and up to $3.9B in total contingent consideration -- -- Companies to co-commercialize and split profits in the U.S.; Arcellx to receive low to mid-teen royalties outside the U.S. -- -- Arcellx to continue independently progressing its development pipeline and researching new product candidates beyond myeloma -- -- Arcellx to host a conference call and webcast today at 5:45 a.m. PT -- REDWOOD CITY, Calif., and SANTA MONICA, Calif., Dec. 9, 2022 /PRNewswire/ -- Arcellx
Arcellx (NASDAQ:ACLX) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 4 1 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $81.5, a high estimate of $87.00, and a low estimate of $70.00. A decline of 1.81% from the prior average price target
Canaccord Genuity analyst John Newman maintains Arcellx (NASDAQ:ACLX) with a Buy and maintains $85 price target.
Ratings for Arcellx (NASDAQ:ACLX) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 1 0 0 0 2M Ago 4 1 0 0 0 3M Ago 1 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $81.0, a high estimate of $87.00, and a low estimate of $70.00. This current average has decreased by 1.94% from the previous
144 - Arcellx, Inc. (0001786205) (Subject)
10-Q - Arcellx, Inc. (0001786205) (Filer)
144 - Arcellx, Inc. (0001786205) (Subject)
SC 13G/A - Arcellx, Inc. (0001786205) (Subject)
SC 13G/A - Arcellx, Inc. (0001786205) (Subject)
SC 13G/A - Arcellx, Inc. (0001786205) (Subject)
REDWOOD CITY, Calif., June 21, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Maryam Abdul-Kareem, J.D., as General Counsel. Ms. Abdul-Kareem brings extensive legal and business expertise in the biopharmaceutical industry, including serving in senior positions at Kinnate Biopharma and AstraZeneca. At Arcellx, she will oversee a broad spectrum of legal, contracts, and compliance matters.
FOSTER CITY, Calif., May 23, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Michelle Gilson as Chief Financial Officer. Ms. Gilson joins Arcellx from Canaccord Genuity, where most recently she served as Managing Director and Senior Equity Research Analyst covering biotechnology companies. Ms. Gilson will oversee the company's finance function and will play a key role in overall corporate strategy.
-- Replaces Lewis T. "Rusty" Williams, M.D., on Board of Directors -- FOSTER CITY, Calif., May 16, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Olivia Ware to its Board of Directors. Ms. Ware, a successful executive, brings a wealth of knowledge from her more than 20 years of experience in biotech and pharmaceutical drug development, commercialization, and healthcare management. "On
4 - Arcellx, Inc. (0001786205) (Issuer)
4 - Arcellx, Inc. (0001786205) (Issuer)
4 - Arcellx, Inc. (0001786205) (Issuer)